NCT03969849View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

March 27, 2020

Study Completion Date

March 27, 2020

Conditions
Healthy VolunteersBirch Pollen Allergy
Interventions
DRUG

REGN5713-5714-5715

Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

DRUG

Matching placebo

Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Trial Locations (3)

Unknown

Regeneron Study Site, Antwerp

Regeneron Study Site, Ghent

Regeneron Study Site, Leuven

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03969849 - Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter